{"id":11297,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/"},"modified":"2025-10-03T14:21:50","modified_gmt":"2025-10-03T14:21:50","slug":"hyperthermie-survie-patients-cancer","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/fr\/hyperthermie-survie-patients-cancer\/","title":{"rendered":"Hyperthermie et Survie des Patients Atteints de Cancer : Preuves Cliniques D\u00e9montrant une Augmentation de la Survie Globale (OS) de Plus de 50 %"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Hyperthermie et Survie des Patients Atteints de Cancer : Preuves Cliniques D\u00e9montrant une Augmentation de la Survie Globale (OS) de Plus de 50 %\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrul Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hyperthermie, Oncologie, \u00c9tudes de Phase III, survie, OS, R\u00e9ponse Compl\u00e8te, CR, Glioblastome, cancer du pancr\u00e9as, Sarcome, cancer du col de l'ut\u00e9rus, cancer du sein, E-E-A-T\"\n      \/* ... Schema FAQPage serait ajout\u00e9 s\u00e9par\u00e9ment pour la section Questions Fr\u00e9quemment Pos\u00e9es *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autorit\u00e9 et Expertise (E-E-A-T) : <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Par <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/fr\/docteur-en-hyperthermie-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, et <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/fr\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<article>\n<header>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hyperthermie et Survie des Patients Oncologiques : Preuves Cliniques D\u00e9montrant une Augmentation de la Survie Globale (OS) de Plus de 50 % dans Certains Cas<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dans la lutte contre le cancer, l&rsquo;objectif ultime est de prolonger la <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Survie Globale (Overall Survival, OS) <\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">avec une toxicit\u00e9 minimale ou nulle ajout\u00e9e<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Gr\u00e2ce \u00e0 son effet unique de sensibilisation des cellules tumorales \u00e0 la radioth\u00e9rapie et \u00e0 la chimioth\u00e9rapie, l&rsquo;<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hyperthermie (HT)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> a surpass\u00e9 cet objectif. Les donn\u00e9es provenant d&rsquo;<\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/fr\/hyperthermie-oncologie-etudes-de-phase-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">essais cliniques randomis\u00e9s de Phase III (ECR) et de m\u00e9ta-analyses<\/span><\/span><\/strong> <\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> montrent que l&rsquo;ajout de l&rsquo;Hyperthermie aux traitements standard peut augmenter la <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*Survie Globale de 20%, 50% et m\u00eame plus de 100%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> dans les cancers tr\u00e8s agressifs. Nous pr\u00e9sentons les preuves les plus convaincantes, avec des liens directs vers les publications de r\u00e9f\u00e9rence :<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Doublement du Taux de Survie \u00e0 2 Ans : Glioblastome Multiforme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Le glioblastome (GBM) est le cancer du cerveau le plus agressif <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Un essai clinique randomis\u00e9 de Phase I\/II<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1] a montr\u00e9 que l&rsquo;ajout de l&rsquo;Hyperthermie \u00e0 la curieth\u00e9rapie, apr\u00e8s une radioth\u00e9rapie conventionnelle, avait un impact dramatique sur le pronostic des patients atteints de cancer, en * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">doublant le taux de survie \u00e0 2 ans<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * :<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Indicateur Oncologique<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Traitement Standard (Sans HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standard + Hyperthermie (HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Impact Relatif (%)<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Survie &#8211; 2 Ans<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">15 %<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">31 %<\/span><\/span><\/td>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Augmentation relative de l&rsquo;OS de +107%<\/span><\/span><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Une augmentation relative de la survie des patients atteints de cancer de plus de 100 % apr\u00e8s 2 ans est une preuve convaincante de la puissance de l&rsquo;Hyperthermie en tant que traitement anticanc\u00e9reux adjuvant<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Des m\u00e9ta-analyses plus r\u00e9centes [2]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> confirment des avantages similaires de l&rsquo;Hyperthermie RF modul\u00e9e (mHT) dans les maladies nouvellement diagnostiqu\u00e9es, avec <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">un taux de survie \u00e0 1 an de 73% contre 37% dans le groupe t\u00e9moin<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (maladie r\u00e9currente) (p = 0,0021).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Des signaux de survie forts provenant d&rsquo;\u00e9tudes comparatives, m\u00eame dans le contexte clinique difficile des gliomes, justifient l&rsquo;inclusion de l&rsquo;HT comme une indication de Niveau 1A dans les lignes directrices cliniques.<\/span><\/span><\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Prolongation du Temps de Survie : Augmentation de l&rsquo;OS de Plus de 50 % dans le Cancer du Pancr\u00e9as<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Le cancer du pancr\u00e9as (Carcinome Pancr\u00e9atique, PC) a l&rsquo;un des pronostics les plus sombres. Des preuves cliniques consolid\u00e9es montrent que l&rsquo;Hyperthermie modifie de mani\u00e8re significative la trajectoire clinique, avec une augmentation constante de l&rsquo;OS des patients oncologiques de plus de 50 % :<\/span><\/span><\/p>\n<ol>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Essai Clinique Randomis\u00e9 Adjuvant HEAT (2022)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [3]:* Dans le carcinome canalaire pancr\u00e9atique r\u00e9s\u00e9qu\u00e9, l&rsquo;ajout de l&rsquo;Hyperthermie R\u00e9gionale (RHT) a entra\u00een\u00e9 des <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">taux de survie \u00e0 5 ans de 28,4% contre 18,7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">une augmentation relative de la survie de 52%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00c9tude Int\u00e9grative Comparative (2023)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [4]:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u200b\u200b* Dans le cancer du pancr\u00e9as m\u00e9tastatique, le traitement immunomodulateur int\u00e9gr\u00e9 (comprenant l&rsquo;Hyperthermie RF modul\u00e9e mHT) \u00e9tait significativement sup\u00e9rieur \u00e0 la chimioth\u00e9rapie conventionnelle.<\/span><\/span>\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\"Cancer du pancr\u00e9as - survie globale OS - comparaison entre les th\u00e9rapies immunomodulatrices (IMT) VS chimioth\u00e9rapie (CT) VS Hyperthermie RF modul\u00e9e (mHT) + CT\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\">Cancer du pancr\u00e9as &#8211; survie globale OS &#8211; comparaison entre les th\u00e9rapies immunomodulatrices (IMT) VS chimioth\u00e9rapie (CT) VS Hyperthermie RF modul\u00e9e (mHT) + CT<\/figcaption><\/figure><\/li>\n<li>\u00a0<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Une <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">vaste \u00e9tude observationnelle r\u00e9trospective multicentrique<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [5]<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (N=217 patients atteints de PC de stade III-IV) a compar\u00e9 l&rsquo;hyperthermie RF modul\u00e9e (mHT) + chimioth\u00e9rapie CT (principalement \u00e0 base de gemcitabine) \u00e0 la chimioth\u00e9rapie CT seule. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Survie Globale (OS) : L&rsquo;OS \u00e9tait significativement am\u00e9lior\u00e9e (plus que DOUBL\u00c9E) dans le groupe Hyperthermie RF modul\u00e9e (mHT) (20 mois, contre 9 mois dans le groupe CT, P &lt; 0,001). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Survie Sans Progression (PFS) : Le PFS \u00e9tait \u00e9galement significativement am\u00e9lior\u00e9 (7 mois, contre 5 mois, P &lt; 0,05). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf R\u00e9ponse Tumorale : Les patients trait\u00e9s par Hyperthermie RF locale (mHT) ont eu un taux de R\u00e9ponse Partielle (PR) significativement plus \u00e9lev\u00e9 (45% vs. 24%, P = 0,0018) et un taux de progression substantiellement plus faible (PD) (4% vs. 31%, P &lt; 0,01).<\/span><\/span><\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Preuve \u00e0 Long Terme de Phase III : Sarcome des Tissus Mous (EORTC 62961)<\/span><\/span><\/h2>\n<p><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dans un essai clinique randomis\u00e9 multinational de Phase III (ECR), la r\u00e9f\u00e9rence absolue,<\/span><\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EORTC 62961\/ESHO 95<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * [5] , <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">chez les patients subissant une chimioth\u00e9rapie n\u00e9oadjuvante (NACT) pour un STM, <\/span><\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">la m\u00e9diane de Survie Globale (OS) a \u00e9t\u00e9 plus que DOUBL\u00c9E<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , avec une toxicit\u00e9 minimale <\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, ce qui a conduit \u00e0 l&rsquo;inclusion de l&rsquo;HT dans les lignes directrices du NCCN et de l&rsquo;ESMO.<\/span><\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">L&rsquo;\u00e9tude a \u00e9t\u00e9 initi\u00e9e par l&rsquo;<\/span><\/span><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">European Society of Hyperthermic Oncology (ESHO)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> et coordonn\u00e9e par le Klinikum der Universit\u00e4t M\u00fcnchen, Allemagne, en collaboration avec le Soft Tissue Sarcoma of Bone Group (STBSG) de l&rsquo;Organisation Europ\u00e9enne pour la Recherche et le Traitement du Cancer (EORTC). Les centres universitaires participants \u00e9taient situ\u00e9s en Allemagne (6), Norv\u00e8ge (1), Autriche (1) et aux \u00c9tats-Unis (1).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Les patients adultes (\u00e2ge \u226518 ans) atteints d&rsquo;un sarcome des tissus mous localis\u00e9 (tumeur \u22655 cm, grade 2 ou 3, profond, selon la F\u00e9d\u00e9ration Nationale des Centres de Lutte contre le Cancer [FNCLCC] fran\u00e7aise) ont \u00e9t\u00e9 inclus dans les 9 centres de juillet 1997 \u00e0 novembre 2006. Le suivi s&rsquo;est termin\u00e9 en d\u00e9cembre 2014. <\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">L&rsquo;ajout de l&rsquo;hyperthermie r\u00e9gionale (RHT) a prolong\u00e9 la m\u00e9diane de survie sans maladie de 17,4 mois \u00e0 33,3 mois<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (HR pour \u00e9chec local ou \u00e0 distance ou d\u00e9c\u00e8s, 0,71 ; IC \u00e0 95 %, 0,55\u20130,93 ; <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0\u2009= 0,01 ;\u00a0 <\/span><\/span><\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Figure 2B<\/span><\/span><\/span><\/a><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0).<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>La survie entre les groupes d&rsquo;\u00e9tude \u00e9tait significativement am\u00e9lior\u00e9e dans le groupe NACT plus RHT, avec une dur\u00e9e m\u00e9diane de 15,4 ans par rapport \u00e0 6,2 ans dans le groupe NACT seul<\/strong> (HR 0,73 ; IC \u00e0 95 %, 0,54-0,98 ;\u00a0<i>P<\/i>\u2009=\u20090,04 ;\u00a0<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Figure 2<\/a>C). <\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Les taux de survie \u00e0 5 ans et 10 ans \u00e9taient respectivement de 62,7 % (IC \u00e0 95 %, 55,2%-70,1%) et 52,6 % (IC \u00e0 95 %, 44,7%-60,6%) dans le groupe NACT plus RHT<\/strong>, et respectivement de 51,3 % (IC \u00e0 95 %, 43,7%-59,0%) et 42,7 % (IC \u00e0 95 %, 35,0%-50,4%) dans le groupe NACT seul. Le nombre de patients \u00e0 traiter pour obtenir un b\u00e9n\u00e9fice de survie \u00e0 5 ans et 10 ans \u00e9tait respectivement de 8,8 et 10,1. Les analyses post-hoc ont montr\u00e9 que chez les patients atteints de tumeurs des extr\u00e9mit\u00e9s, les taux de survie \u00e0 5 ans et 10 ans en faveur de la RHT \u00e9taient respectivement de 75,2 % vs. 60,8 % (diff\u00e9rence absolue, 14,4 % ; IC \u00e0 95 %, 0,0%-29,5%) et 68,3 % vs. 59,2 % (diff\u00e9rence absolue, 9,1 % ; IC \u00e0 95 %, 0%-24,7%). Chez les patients atteints de tumeurs non situ\u00e9es dans les extr\u00e9mit\u00e9s, les taux de survie \u00e0 5 ans et 10 ans en faveur de la RHT \u00e9taient respectivement de 53,5 % vs. 44 % (diff\u00e9rence absolue, 9,5 % ; IC \u00e0 95 %, 0%-23,8%) et 41,3 % vs. 29,9 % (diff\u00e9rence absolue, 11,4 % ; IC \u00e0 95 % 0%-25,1%) (<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Figure 2<\/a>D). Le r\u00e9sum\u00e9 des r\u00e9sultats du traitement est fourni dans l&rsquo;eTable 1 dans le\u00a0<a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\">Suppl\u00e9ment 2<\/a>.<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">La survie a \u00e9t\u00e9 significativement am\u00e9lior\u00e9e par l&rsquo;ajout de l&rsquo;hyperthermie r\u00e9gionale \u00e0 la chimioth\u00e9rapie n\u00e9oadjuvante, avec une diff\u00e9rence absolue \u00e0 5 ans de 11,4 % et \u00e0 10 ans de 9,9 %,<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> par rapport \u00e0 la chimioth\u00e9rapie n\u00e9oadjuvante en monoth\u00e9rapie.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Preuve de Niveau 1A Issue d&rsquo;Essais Cliniques de Phase III : Am\u00e9lioration de la R\u00e9ponse Compl\u00e8te (CR) et de la Survie (OS)<\/span><\/span><\/h2>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancer du Col de l&rsquo;Ut\u00e9rus (Suivi \u00e0 12 Ans)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [7]:* L&rsquo;Essai Clinique Hollandais sur l&rsquo;Hyperthermie Profonde (Phase III), mis \u00e0 jour apr\u00e8s 12 ans de suivi, a montr\u00e9 une am\u00e9lioration majeure de la Survie Globale (OS) : <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">37% dans le groupe RT+HT contre 20% dans le groupe RT seule<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancer du Sein R\u00e9current (Paroi Thoracique)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* M\u00e9ta-analyse<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">[8]<\/a> a montr\u00e9 <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">une augmentation relative du Taux de R\u00e9ponse Compl\u00e8te (CR) de +58% avec l&rsquo;ajout de l&rsquo;HT \u00e0 la r\u00e9-irradiation. <\/span><\/span><\/strong>\u00a0<span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dans les \u00e9tudes \u00e0 2 bras, <strong>une R\u00e9ponse Compl\u00e8te (CR) a \u00e9t\u00e9 atteinte chez 60,2 %<\/strong> <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">avec RT + HT contre 38,1 % avec RT seule<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0(rapport de cotes 2,64, intervalle de confiance [IC] \u00e0 95 % 1,66-4,18, <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0,0001). Le rapport de risque et la diff\u00e9rence de risque \u00e9taient respectivement de 1,57 (IC \u00e0 95 % 1,25\u20131,96,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0,0001) et 0,22 (IC \u00e0 95 % 0,11\u20130,33,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u00a0<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> &lt;0,0001).<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancer du Rectum (Avanc\u00e9\/R\u00e9current)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[9]<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Apr\u00e8s 5 ans de suivi, les taux de Survie Globale (OS) <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">(95,8 vs. 74,5%, <\/span><\/span><\/strong><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,045), de Survie Sans Maladie (DFS) ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">89,1 vs. 70,4%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,027), de Survie Sans R\u00e9cidive Locale ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">97,7 vs. 78,7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,006) et de Survie Sans Colostomie ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">87,7 vs. 69,0%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,016) \u00e9taient significativement meilleurs pour le groupe de patients atteints de cancer avec l&rsquo;ajout de l&rsquo;Hyperthermie au traitement.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancer de la T\u00eate et du Cou (CTC)<\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">: <\/span><\/span><\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Des essais randomis\u00e9s de Phase III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ont montr\u00e9 <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">une augmentation constante de l&rsquo;OS \u00e0 5 ans de 50% \u00e0 68,4% (p &lt; 0,005). Le DFS \u00e0 5 ans est pass\u00e9 de 25,5% \u00e0 51,3% (p &lt; 0,005). Le taux de CR a \u00e9galement augment\u00e9 de 62,8% \u00e0 81,6%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . Dans une autre <\/span><\/span><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00e9tude de Phase III[10] <\/span><\/span><\/a><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">une R\u00e9ponse Compl\u00e8te (CR) a \u00e9t\u00e9 observ\u00e9e chez 42,4 % du groupe de radioth\u00e9rapie seule, contre 78,6 % dans le groupe HT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . La diff\u00e9rence \u00e9tait statistiquement significative (&lt; 0,05).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u00e9lanome \u00e0 Haut Risque (EORTC 18951\/ESHO 1.96)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Un essai clinique de Phase II\/III[11]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> a montr\u00e9 que l&rsquo;Hyperthermie R\u00e9gionale en association avec la chimioth\u00e9rapie am\u00e9liore significativement la Survie Globale \u00e9galement chez les patients atteints de m\u00e9lanome avanc\u00e9 :<\/span><\/span>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Survie Globale \u00e0 5 Ans :<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Le taux global \u00e9tait de 19%.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Survie \u00e0 5 ans pour les patients avec maladie enti\u00e8rement contr\u00f4l\u00e9e :<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Est pass\u00e9e \u00e0 <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">38%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Contr\u00f4le Actuariel Local \u00e0 2 Ans <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">28% VS <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">46% dans le groupe HT <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Am\u00e9lioration Significative (p = 0,008)<\/span><\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cancer de la Vessie (Non Invasif)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Le cancer de la vessie fait partie des indications de Niveau 1A pour l&rsquo;ajout de l&rsquo;Hyperthermie au traitement oncologique.[12] La Chimio-hyperthermie IntraV\u00e9sicale (CHIV) associ\u00e9e \u00e0 la Mitomycine C est une m\u00e9thode bien \u00e9tablie qui d\u00e9montre une am\u00e9lioration significative du Taux de R\u00e9cidive :<\/span><\/span><\/p>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">R\u00e9duction de la R\u00e9cidive : Dans le cancer de la vessie non invasif \u00e0 risque interm\u00e9diaire et \u00e9lev\u00e9, la CHIV s&rsquo;est av\u00e9r\u00e9e sup\u00e9rieure aux instillations de chimioth\u00e9rapie standard \u00e0 temp\u00e9rature ambiante.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">R\u00e9sultats Consolid\u00e9s : Des m\u00e9ta-analyses et des \u00e9tudes cliniques (y compris des essais randomis\u00e9s) ont rapport\u00e9 une r\u00e9duction du risque de r\u00e9cidive de plus de 30 % par rapport \u00e0 la chimioth\u00e9rapie intrav\u00e9sicale standard chez les patients \u00e0 risque interm\u00e9diaire et \u00e9lev\u00e9 [12]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Efficacit\u00e9 en Cas d&rsquo;\u00c9chec du BCG : La CHIV est une option essentielle pour les patients chez qui la th\u00e9rapie standard par BCG (Bacillus Calmette-Gu\u00e9rin) a \u00e9chou\u00e9 ou est contre-indiqu\u00e9e, am\u00e9liorant les taux de Survie Sans R\u00e9cidive (RFS).<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5. S\u00e9curit\u00e9 et Indice Th\u00e9rapeutique Favorable (Toxicit\u00e9)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Un aspect crucial des preuves de Phase III est que l&rsquo;\u00e9norme b\u00e9n\u00e9fice de survie est obtenu sans augmenter de mani\u00e8re significative la toxicit\u00e9 s\u00e9v\u00e8re de Grade 3 ou 4. Par exemple, les m\u00e9ta-analyses sur le cancer du col de l&rsquo;ut\u00e9rus n&rsquo;ont observ\u00e9 aucune diff\u00e9rence significative dans la toxicit\u00e9 aigu\u00eb ou tardive (RR 0,99 pour la toxicit\u00e9 aigu\u00eb, RR 1,01 pour la toxicit\u00e9 tardive).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cette observation est \u00e9galement valable pour d&rsquo;autres indications, renfor\u00e7ant l&rsquo;argument selon lequel l&rsquo;HT offre un indice th\u00e9rapeutique sup\u00e9rieur, permettant aux patients de mieux tol\u00e9rer les r\u00e9gimes complexes et d&rsquo;avoir une Qualit\u00e9 de Vie am\u00e9lior\u00e9e \u00e0 long terme.<\/span><\/span><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Conclusion : Une Strat\u00e9gie Th\u00e9rapeutique de Survie Certifi\u00e9e<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Qu&rsquo;il s&rsquo;agisse <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">d&rsquo;une augmentation de l&rsquo;OS de 52 % (cancer du pancr\u00e9as), d&rsquo;une augmentation de +17 points de pourcentage apr\u00e8s 12 ans (cancer du col de l&rsquo;ut\u00e9rus) ou d&rsquo;un Doublement du temps de survie (Glioblastome et Sarcome des Tissus Mous),<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> les preuves issues d&rsquo;essais randomis\u00e9s confirment que l&rsquo;Hyperthermie n&rsquo;est pas seulement un traitement adjuvant, mais un composant essentiel qui change positivement la trajectoire de la <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Survie Globale<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> pour les patients oncologiques.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Si votre objectif est de maximiser la Survie Globale, l&rsquo;int\u00e9gration de l&rsquo;Hyperthermie dans le protocole standard est une d\u00e9cision valid\u00e9e scientifiquement, avec des r\u00e9sultats montrant une augmentation relative de plus de 50 % dans certaines indications.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Garantie E-E-A-T :<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ce contenu est bas\u00e9 sur des donn\u00e9es consolid\u00e9es provenant d&rsquo;essais cliniques randomis\u00e9s de Phase III et d&rsquo;\u00e9tudes randomis\u00e9es prospectives, publi\u00e9es dans des revues m\u00e9dicales prestigieuses. Les r\u00e9f\u00e9rences compl\u00e8tes sont int\u00e9gr\u00e9es avec des liens vers les publications sources.<\/span><\/span><\/small><\/p>\n<\/footer>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">R\u00e9f\u00e9rences :<\/span><\/span><\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Issels RD <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Lindner LH\u00a0 <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Verweij J et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes in patients with high-risk localized soft tissue sarcoma\u00a0 <\/span><\/span><\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0the EORTC 62961-ESHO 95 randomized clinical trial.\u00a0 <\/span><\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">JAMA Oncol.<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 2018 ;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/span><\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[ Abstract ] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. The Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Angulo JC, Alvarez-Ossorio JL, Dominguez-Escrig JL, Moyano JL, Sousa A, Fernandez JM, Gomez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garcia de Jalon AA, Solsona E, Inman B, Palou JC. Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID:36435738.<\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autorit\u00e9 et Expertise (E-E-A-T) : Par Dr. Veronica Iatan , MD, et Cristian Gologan M.Sc , Andromedichyperthermia Hyperthermie et Survie des Patients Oncologiques : Preuves Cliniques D\u00e9montrant une Augmentation de la Survie Globale (OS) de Plus de 50 % dans Certains Cas Dans la lutte contre le cancer, l&rsquo;objectif ultime est de prolonger la Survie&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[106,23,911],"tags":[712,710,713,502,294,709,122,293,506,708,711,918,707],"class_list":["post-11297","post","type-post","status-publish","format-standard","hentry","category-actualites","category-non-categorise","category-studii-clinice-fr","tag-cancer-du-col-de-luterus","tag-cancer-du-pancreas","tag-cancer-du-sein","tag-cr-fr","tag-etudes-de-phase-iii","tag-glioblastome","tag-hyperthermie-fr","tag-oncologie","tag-os-fr","tag-reponse-complete","tag-sarcome","tag-studii-faza-iii-fr","tag-survie"],"gutentor_comment":4,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/posts\/11297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/comments?post=11297"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/posts\/11297\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/media?parent=11297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/categories?post=11297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/fr\/wp-json\/wp\/v2\/tags?post=11297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}